Canaccord Genuity Remains a Buy on OrganiGram Holdings (OGI)
The Materials sector company, OrganiGram Holdings (OGI), has received a rating update from a Wall Street analyst yesterday. Analyst Matt Bottomley from Canaccord Genuity reiterated a Buy rating, with a C$7.50 price target.
Bottomley has an average return of 50.3% when recommending OrganiGram Holdings.
According to TipRanks.com, Bottomley is ranked #546 out of 5107 analysts.
OrganiGram Holdings has an analyst consensus of Strong Buy, with a price target consensus of C$10.21, a 121.5% upside from current levels. In a report issued on December 7, Beacon also maintained a Buy rating on the stock with a C$11.50 price target.
The company has a one-year high of C$8.55 and a one-year low of C$3.26. Currently, OrganiGram Holdings has an average volume of 1.41M.
OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. Its products include strains, cannabis oils, and vaporizrs. The company was founded in 2013 and is headquartered in Moncton, Canada.
The company’s shares closed on Wednesday at C$4.61.